# Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

> **NCT05304351** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Curevo Inc** · enrollment: 1516 (actual)

## Conditions studied

- Herpes Zoster
- Shingles

## Interventions

- **BIOLOGICAL:** Amezosvatein Antigen High Dose Arm A
- **BIOLOGICAL:** Amezosvatein Antigen Low Dose Arm B
- **BIOLOGICAL:** Shingrix
- **BIOLOGICAL:** Amezosvatein Adjuvant Dose Arm D
- **BIOLOGICAL:** Amezosvatein Adjuvant Dose Arm F
- **BIOLOGICAL:** Amezosvatein Adjuvant Dose Arm H
- **BIOLOGICAL:** Amezosvatein Adjuvant Dose Arm J
- **BIOLOGICAL:** Amezosvatein Adjuvant Dose Arm L

## Key facts

- **NCT ID:** NCT05304351
- **Lead sponsor:** Curevo Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2032-03-06
- **Target enrollment:** 1516 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304351, "Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05304351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*